Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-18T21:36:48.810Z Has data issue: false hasContentIssue false
  • English
  • Français

Gamma-Aminobutyric Acid (GABA) in the CSF of Schizophrenic Patients Before and After Neuroleptic Treatment

Published online by Cambridge University Press:  29 January 2018

D. Lichtshtein ,
J. Dobkin ,
R. P. Ebstein ,
J. Biederman ,
R. Rimon  and
R. H. Belmaker
D. Lichtshtein
Affiliation:
Department of Physiology, Hadassah-Hebrew-University Medical School Jerusalem, Israel
J. Dobkin
Affiliation:
Department of Physiology, Hadassah-Hebrew-University Medical School Jerusalem, Israel
R. P. Ebstein
Affiliation:
Department of Research, Jerusalem Mental Health Centre—Ezrat Nashim, PO Box 140, Jerusalem, Israel
J. Biederman
Affiliation:
Department of Research, Jerusalem Mental Health Centre—Ezrat Nashim, PO Box 140, Jerusalem, Israel
R. Rimon
Affiliation:
Department of Research, Jerusalem Mental Health Centre—Ezrat Nashim, PO Box 140, Jerusalem, Israel
R. H. Belmaker
Affiliation:
Department of Research, Jerusalem Mental Health Centre—Ezrat Nashim, PO Box 140, Jerusalem, Israel
Get access Rights & Permissions [Opens in a new window]

Abstract

Gamma-aminobutyric acid (GABA) levels in the CSF were measured in 9 normal individuals, 17 drug-free schizophrenic patients and 10 of these same schizophrenic patients after neuroleptic treatment. There was no significant difference between CSF level of GABA in the control group compared to those in schizophrenic patients; however, 6 of the 7 lowest GABA levels were from schizophrenic patients. There was a significant decline of 12 per cent in mean GABA levels in the CSF after a mean of two months of neuroleptic treatment.

Type
Papers
Information
The British Journal of Psychiatry , Volume 132 , Issue 2 , February 1978 , pp. 145 - 148
Copyright
Copyright © Royal College of Psychiatrists, 1978 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baxter, C. F. (1972) Assay of y-aminobutyric acid and enzymes involved in its metabolism. In Methods of Neurochemistry, 3 (ed. Fried, R.). New York: Marcel Dekker.Google Scholar
Biederman, J., Rimon, R., Ebstein, R. P., Belmaker, R. H. & Davidson, J. T. (1977a) Cyclic AMP in the CSF of patients with schizophrenia. British Journal of Psychiatry, 130, 64–7.Google Scholar
Biederman, J., Rimon, R., Ebstein, R. P. & Belmaker, R. H. (1977b) Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patients. Neuropsychobiology. In press.Google Scholar
Bowers, M. B. (1974) Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry, 31, 50–4.Google Scholar
Collins, G. G. S. (1973) Effect of aminooxyacetic acid, thiosemicarbazide and haloperidol on the metabolism and half-lives of glutamate and GABA in rat brain. Biochemical Pharmacology, 22, 101–11.CrossRefGoogle Scholar
Costa, E., Guidotti, A. & Mao, C. C. (1976) A GABA hypothesis for the action of benzodiazepines. In GABA in Nervous System Function (eds Roberts, E., Chase, T. N. and Tower, D. B.). New York: Raven Press.Google Scholar
Curtis, D. R. & Crawford, J. M. (1969) Central synaptic transmission-microelectrophoretic studies. Annual Review of Pharmacology, 9, 209–40.Google Scholar
Ebstein, R. P., Biederman, J., Rimon, R., Zohar, J. & Belmaker, R. H. (1976) Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment. Psychopharmacology, 51, 71–4.Google Scholar
Glaeser, B. S. & Hare, T. A. (1975) Measurement of GABA in human cerebrospinal fluid. Biochemical Medicine, 12, 174–82.Google Scholar
Glaeser, B. S., Vogel, W. H., Oleweiler, D. B. & Hare, T. A. (975) GABA levels in cerebrospinal fluid of patients with Huntington's chorea: a preliminary report. Biochemical Medicine, 12, 380–5.Google Scholar
Goodwin, F. K. & Post, R. M. (1975) Cerebrospinal fluid amine metabolites in affective illness and schizophrenia: clinical and pharmacological studies. Psychopharmacology Communications, 1(6), 641–53.Google Scholar
Kim, J. S. & Hassler, R. (1975) Effects of acute haloperidol on the gamma-aminobutyric acid system in rat striatum and substantia nigra. Brain Research, 88, 150–3.Google Scholar
Langer, D. H., Brown, G. L. V., Bunney, W. E. Jr & van Kammen, D. P. (1975) Gamma-aminobutyric acid in CSF in schizophrenia. New England Journal of Medicine, 293, 201.Google ScholarPubMed
Post, R. M., Fink, E., Carpenter, W. T. & Goodwin, F. K. (1975) Cerebrospinal fluid amine metabolites in acute schizophrenia. Archives of General Psychiatry, 32, 1063–9.Google Scholar
Roberts, E. (1972) An hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neurosciences Research Programme Bulletin, 10, 468–80.Google Scholar
Smith, C. C., Tallman, J. F., Post, R. M., van Kammen, D. P., Jimmerson, D. C. & Brown, G. L. (1976) An examination of baseline and drug-induced levels of cyclic nucleotides in the cerebrospinal fluid of control and psychiatric patients. Life Sciences, 19, 131–6.Google Scholar
Snyder, S. H., Banerjee, S. P., Yamamura, H. I. & Greenberg, D. (1974) Drugs, neurotransmitters and schizophrenia. Science, 184, 1243–53.Google Scholar
Stevens, J., Wilson, K. & Foote, W. (1974) GABA blockage, dopamine and schizophrenia: experimental studies in the cat. Psychopharmacologia (Berl.), 39, 105–19.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.